Quarterly ResultAug 7, 2026, 04:21 PM
Alps Group Inc FY26 Revenue Up 44% to $4.9M; Net Loss $2.1M
AI Summary
Alps Group Inc reported its fiscal year 2026 financial results, with revenue growing 44% to $4.9 million, driven by cellular therapy, medical testing, and healthcare products. The company's net loss improved to $2.1 million from $2.6 million in the prior year, though gross margin decreased to 32%. Key business highlights include its Nasdaq listing in October 2025, advancements in its cellular therapy pipeline, and expanded laboratory accreditation for Whole Genome Sequencing.
Key Highlights
- Revenue increased 44% to $4.9 million for the fiscal year ended March 31, 2026.
- Net loss for FY26 was $2.1 million, an improvement from $2.6 million in FY25.
- Gross profit rose to $1.6 million in FY26, up from $1.3 million in FY25.
- Gross margin was approximately 32% for FY26, down from 39% in FY25.
- R&D expenses decreased to $61,155 in FY26 from $169,987 in FY25.
- Began trading on the Nasdaq Global Market under "ALPS" in October 2025.
- MyGenome Sdn. Bhd. expanded laboratory accreditation to include Whole Genome Sequencing (WGS).
- Appointed Cheing Lye-Ping as Chief Financial Officer.
Price Impact
More from ALPS